Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) have substantial new evidence supporting their use in managing endocrine disorders.
Clinicians should consider the new evidence on GLP-1RAs for managing various endocrine disorders.
StrongSupportsmedium confidence
From the substantial new evidence published in 2024, 10 studies are highlighted that offer critical information for clinicians who manage or comanage patients with endocrine disorders including prediabetes, diabetes, obesity, and hyperparathyroidism.
Why this rating
Based on the mention of multiple studies providing critical information.
Source
Endocrinology: What You May Have Missed in 2024
Mohamed Aman et al. · Annals of Internal Medicine · 2025
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →